An antibody drug conjugate (ADC) therapy being developed by BioNTech and DualityBio for treatment of HER2 positive advanced stage breast cancer has met its primary endpoint in a key Phase III trial in China.

Trastuzumab pamirtecan was shown to be more effective than Roche’s approved ADC trastuzumab emtansine (Kadycla) in a Phase III trial comparing the two ADCs in patients with HER2-positive unresectable or metastatic breast cancer.

Although the exact results were not yet released by the companies, the trial met its primary endpoint of a significant improvement in progression free survival and DualityBio announced it plans to discuss steps towards approval in China with the country’s regulatory agency, the Center for Drug Evaluation of the National Medical Products Administration.

ADC

See Full Page